Cargando…

The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus

Respiratory syncytial virus is a leading cause of lower respiratory tract illness among infants, the elderly and immunocompromised individuals. Currently, there is no effective vaccine or disease modifying treatment available and novel interventions are urgently required. Cathelicidins are cationic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Currie, Silke M., Findlay, Emily Gwyer, McHugh, Brian J., Mackellar, Annie, Man, Tian, Macmillan, Derek, Wang, Hongwei, Fitch, Paul M., Schwarze, Jürgen, Davidson, Donald J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758310/ https://www.ncbi.nlm.nih.gov/pubmed/24023689 http://dx.doi.org/10.1371/journal.pone.0073659

Ejemplares similares

Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans
por: Currie, Silke M., et al.
Publicado: (2016)

Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37
por: Barlow, Peter G., et al.
Publicado: (2011)

Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages
por: Li, Hsin-Ni, et al.
Publicado: (2009)

The Role of Cathelicidin LL-37 in Cancer Development
por: Piktel, Ewelina, et al.
Publicado: (2015)

Cathelicidin Host Defence Peptide Augments Clearance of Pulmonary Pseudomonas aeruginosa Infection by Its Influence on Neutrophil Function In Vivo
por: Beaumont, Paula E., et al.
Publicado: (2014)

Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy
por: Findlay, Emily Gwyer, et al.
Publicado: (2019)

Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells
por: Harcourt, Jennifer L., et al.
Publicado: (2016)

Cathelicidin LL-37 in Health and Diseases of the Oral Cavity
por: Tokajuk, Joanna, et al.
Publicado: (2022)

Citrullination Alters the Antiviral and Immunomodulatory Activities of the Human Cathelicidin LL-37 During Rhinovirus Infection
por: Casanova, Víctor, et al.
Publicado: (2020)

Cationic Host Defence Peptides: Potential as Antiviral Therapeutics
por: Gwyer Findlay, Emily, et al.
Publicado: (2013)

Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses
por: Tripathi, Shweta, et al.
Publicado: (2015)

Pulmonary defense and the human cathelicidin hCAP-18/LL-37
por: Fahy, R. J., et al.
Publicado: (2005)

Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
por: Simonetti, Oriana, et al.
Publicado: (2021)

Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease
por: Reinholz, Markus, et al.
Publicado: (2012)

Transformation of Human Cathelicidin LL-37 into Selective, Stable, and Potent Antimicrobial Compounds
por: Wang, Guangshun, et al.
Publicado: (2014)

Upregulation of human β-defensin-3 and cathelicidin LL-37 in Kaposi’s sarcoma
por: Fathy, Hanan, et al.
Publicado: (2012)

The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs
por: Kuroda, Kengo, et al.
Publicado: (2015)

Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on Streptococcus mutans
por: Guo, Yi-jie, et al.
Publicado: (2016)

The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
por: Babikir, Ibrahim H., et al.
Publicado: (2018)

Significance and Diagnostic Role of Antimicrobial Cathelicidins (LL-37) Peptides in Oral Health
por: Khurshid, Zohaib, et al.
Publicado: (2017)

Cathelicidin LL37 Promotes Osteogenic Differentiation in vitro and Bone Regeneration in vivo
por: Li, Lunhao, et al.
Publicado: (2021)

Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections
por: Majewski, Karol, et al.
Publicado: (2018)

Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia
por: Podaza, Enrique, et al.
Publicado: (2020)

Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus
por: Moreno-Angarita, Alejandro, et al.
Publicado: (2019)

The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis
por: Zhang, Ying, et al.
Publicado: (2013)

The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds
por: Duplantier, Allen J., et al.
Publicado: (2013)

Heparan Sulfate Proteoglycan–Involving Immunomodulation by Cathelicidin Antimicrobial Peptides LL-37 and PR-39
por: Kaneider, Nicole C., et al.
Publicado: (2007)

Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats
por: Weng, Jian-Zhen, et al.
Publicado: (2019)

Cathelicidins PMAP-36, LL-37 and CATH-2 are similar peptides with different modes of action
por: Scheenstra, Maaike R., et al.
Publicado: (2019)

Retraction Note: Human cathelicidin LL-37 enhance the antibiofilm effect of EGCG on Streptococcus mutans
por: Guo, Yi-jie, et al.
Publicado: (2017)

Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13
por: Niemirowicz, Katarzyna, et al.
Publicado: (2017)

Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model
por: Nagaoka, Isao, et al.
Publicado: (2020)

Sequence determinants in the cathelicidin LL-37 that promote inflammation via presentation of RNA to scavenger receptors
por: Kulkarni, Nikhil N., et al.
Publicado: (2021)

Design, synthesis, and characterization of non-hemolytic antimicrobial peptides related to human cathelicidin LL-37
por: Krishnamoorthy, Rajavenkatesh, et al.
Publicado: (2023)

Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands
por: Morizane, Shin, et al.
Publicado: (2011)

Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism
por: Hu, Zhongshuang, et al.
Publicado: (2014)

Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells
por: Niemirowicz, Katarzyna, et al.
Publicado: (2015)

Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells
por: Agier, Justyna, et al.
Publicado: (2018)

Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo
por: Durnaś, Bonita, et al.
Publicado: (2017)

Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites
por: Durnaś, Bonita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9aoflkt8bpb2qllppjg9hg07ia